Natural‐killer Cell Activity and Cytogenetic Response in Chronic Myelogenous Leukaemia Treated With Α‐interferon

Meseri, A.; Delwail, Vincent; Fx, Mahon; Pelletier, D.; Guilhot, Joëlle; Brizard, A.; Gombert, Jean‐Marc; Tanzer, J; Laforest, P. Goube de

doi:10.1111/j.1365-2141.1991.tb04502.x

Cited by 8 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…May be useful in vaccines (191,192) CML, chronic myelogenous leukemia; Flt3L, Fms-like tyrosine kinase ligand 3; IFN, interferon; IL, interleukin; TNF, tumor necrosis factor; GM-CSF, granulocyte-macrophage colony-stimulating factor. Smyth et al Á Cytokines and cancer immunology Immunological Reviews 202/2004 remission of CML (141), and direct evidence correlates the presence of CML peptide-specific T cells, antibodies against CML-associated antigens, and clinical response after IFN therapy (142,143). Other studies suggest that IFN-a stimulates an antileukemia immune response in CML patients via differentiation of highly active DCs (144).…”

Section: Flt3lmentioning

confidence: 99%

“…The most compelling evidence for the importance of the immunomodulatory effects of IFN‐α in its therapeutic activity against human malignancies stems from studies on CML, where IFN‐α can induce hematological remission in 60–80% of patients in early chronic phase CML and occasionally partial or complete cytogenetic remissions (138–140). The upregulation of NK cell activity with IFN‐α treatment correlated with clinical remission of CML (141), and direct evidence correlates the presence of CML peptide‐specific T cells, antibodies against CML‐associated antigens, and clinical response after IFN therapy (142, 143). Other studies suggest that IFN‐α stimulates an antileukemia immune response in CML patients via differentiation of highly active DCs (144).…”

Section: Cytokines In Cancer Immunotherapymentioning

confidence: 99%

See 1 more Smart Citation

Cytokines in cancer immunity and immunotherapy

Smyth

Cretney

Kershaw

et al. 2004

Immunological Reviews

360

256

View full text Add to dashboard Cite

The concept that the immune system recognizes and controls cancer was first postulated over a century ago, and cancer immunity has continued to be vigorously debated and experimentally tested. Mounting evidence in humans and mice supports the involvement of cytokines in tumor initiation, growth, and metastasis. The idea that the immune system detects stressed, transformed, and frankly malignant cells underpins much of the excitement currently surrounding new cytokine therapies in cancer treatment. In this review, we define the contrasting roles that cytokines play in promoting tumor immunity, inflammation, and carcinogenesis. We also discuss the more promising aspects of clinical cytokine use in cancer patients.

show abstract

Section: Flt3lmentioning

confidence: 99%

Section: Cytokines In Cancer Immunotherapymentioning

confidence: 99%

Cytokines in cancer immunity and immunotherapy

Smyth

Cretney

Kershaw

et al. 2004

Immunological Reviews

360

256

View full text Add to dashboard Cite

show abstract

“…E-IFN therapy was carried out as described in detail elsewhere (Guilhot et al, 1991). E-IFN therapy was carried out as described in detail elsewhere (Guilhot et al, 1991).…”

Section: Methodsmentioning

confidence: 99%

Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with α‐interferon

et al. 1993

Self Cite

View full text Add to dashboard Cite

The capacity of alpha-interferon (alpha-IFN) to induce lymphokine activated killer (LAK) cytotoxicity in the absence of interleukin-2 (IL2) has prompted us to test whether or not its ability to reduce dramatically the number of Ph1+ clones in chronic myelogenous leukaemia (CML) patients is in part mediated through the generation of natural killer (NK) or LAK activity. The latter were tested using NK-sensitive (K562) and NK-resistant (Raji) cell lines in a target-cell colony-growth inhibition assay. Effector cells (E) were patient blood mononuclear cells (MC) without in vitro activation prior to their coculture with targets (T). Out of 16 patients tested so far, three failed to undergo cytogenetic remission under alpha-IFN therapy. No NK nor LAK cells could be detected in the MC from two of them while the other displayed NK activity within upper normal limits. 13 patients underwent complete (eight) or partial (five) cytogenetic remission together with significantly high NK and/or LAK activity as compared to normal controls. These observations could favour the hypothesis of an indirect effect of alpha-IFN on leukaemic cells, mediated by cells involved in immune surveillance.

show abstract

“…Especially in CML, IFN-α therapy has been proven effective (170,171), since it induces hematological remission in 60-80% of patients in early chronic phase CML. This clinical remission is correlated with upregulation of NK cell activity (164), presence of antibodies against CML-associated antigens (172) and presence of CML peptide-specific T cells (173).…”

Section: Immune Adjuvants Chemokines and Cytokinesmentioning

confidence: 95%

Immunotherapy in the battle against cancer: David versus Goliath?

Elssen¹

View full text Add to dashboard Cite

People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.• The final author version and the galley proof are versions of the publication after peer review.• The final published version features the final layout of the paper including the volume, issue and page numbers. Link to publication General rightsCopyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.• Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal.If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

show abstract

Natural‐killer Cell Activity and Cytogenetic Response in Chronic Myelogenous Leukaemia Treated With Α‐interferon

Cited by 8 publications

References 10 publications

Cytokines in cancer immunity and immunotherapy

Cytokines in cancer immunity and immunotherapy

Endogenous lymphokine activated killer cell activity and cytogenetic response in chronic myelogenous leukaemia treated with α‐interferon

Immunotherapy in the battle against cancer: David versus Goliath?

Contact Info

Product

Resources

About